钟海静，女，博士，副教授，硕士生导师。2011年毕业于暨南大学国际学院药学（全英）专业，获学士学位。2016年毕业于澳门大学生物医药专业，获博士学位。2016年进入澳门大学中药质量研究国家重点实验室进行博士后研究。2017年到耶鲁大学医学院任访问****/客座研究员。2019年9月进入暨南大学药学院工作。共发表SCI论文53篇，最高影响因子为40.443，其中第一作者（共同一作）18篇，通讯作者1篇，其中IF≥10论文5篇，10>IF≥5论文19篇。中科院1区论文13篇（Chem. Soc. Rev., Angew. Chem. Int. Ed.,和Chem. Sci.等），累计影响因子逾300，H-index=25 （Scopus），单篇最高他引次数逾150次，参与外文专著章节2篇，获得美国专利授权1项，美国临时专利1项。先后参与国家自然科学基金海外及港澳****合作研究基金（**）、澳门科学技术发展基金（098/2014/A2）、澳门大学科学研究基金项目（MYRG2015-00137-ICMS-QRCM, MYRG2016-00151-ICMS-QRCM）。2016年受德国学术交流总署邀请，作为The Postdoc-NeT Fellow到德国交流学习。2016年获澳门特别行政区研究生（博士）科技研发奖（省级科研奖项），2017年获“中国分析测试协会科学技术奖三等奖”（社会科研奖项）。

研究方向：
与炎症、肿瘤、神经退行性疾病相关靶点蛋白的新药研发
主持的科研项目：
暨南大学人才引进项目，2019.10-2022.09，主持
代表性论文：
1.H. J. Zhong(First author), L. Lu, K. H. Leung, C. C. L. Wong, C. Peng, S. C. Yan, D. L. Ma, Z. Cai, H. M. David Wang, C. H. Leung, An iridium(III)-based irreversible protein-protein interaction inhibitor of BRD4 as a potent anticancer agent.Chem. Sci.6, 5400-5408 (2015).
Inside back cover
Impact Factor:9.556
2.H. J. Zhong(First author, Corresponding author), W. Wang, T. S. Kang, H. Yan, Y. Yang, L. Xu, Y. Wang, D. L. Ma, C. H. Leung, A Rhodium(III) Complex as an Inhibitor of Neural Precursor Cell Expressed, Developmentally Down-Regulated 8-Activating Enzyme with in Vivo Activity against Inflammatory Bowel Disease.J. Med.Chem.60, 497-503 (2017).
Impact Factor:6.054
3.H. J. Zhong(First author), B. R. Lee, J. W. Boyle, W. Wang, D. L. Ma, P. W. Hong Chan, C. H. Leung, Structure-based screening and optimization of cytisine derivatives as inhibitors of the menin-MLL interaction.Chem. Commun.52, 5788-5791 (2016).
Impact Factor:6.164
4.C. H. Leung,H. J. Zhong, H. Yang, Z. Cheng, D. S. H. Chan, V. P. Y. Ma, R. Abagyan, C. Y. Wong, D. L. Ma, A metal-based inhibitor of tumor necrosis factor-α.Angew. Chem. Int. Ed.51, 9010-9014 (2012)
Impact Factor:12.257
5.D. L. Ma, H. Z. He, K. H. Leung,H. J. Zhong, D. S. H. Chan, C. H. Leung, Label-free luminescent oligonucleotide-based probes.Chem. Soc. Rev.42, 3427-3440 (2013)
Impact Factor:40.443
6.C. H. Leung,H. J. Zhong, H. Z. He, L. Lu, D. S. H. Chan, D. L. Ma, Luminescent oligonucleotide-based detection of enzymes involved with DNA repair.Chem. Sci.4, 3781-3795 (2013).
Impact Factor:9.556
7.C. H. Leung,H. J. Zhong, D. S. H. Chan, D. L. Ma, Bioactive iridium and rhodium complexes as therapeutic agents.Coord. Chem. Rev.257, 1764-1776 (2013)
Impact Factor:13.476
8.G. J. Yang,H. J. Zhong(Co-first author), C. N. Ko, S. Y. Wong, K. Vellaisamy, M. Ye, D. L. Ma, C. H. Leung, Identification of a rhodium(III) complex as a Wee1 inhibitor against TP53-mutated triple-negative breast cancer cells.Chem. Commun.54, 2463-2466 (2018).
Impact Factor:6.164
9.G. J. Yang, W. Wang, S. W. F. Mok, C. Wu, B. Y. K. Law, X. M. Miao, K. J. Wu,H. J. Zhong, C. Y. Wong, V. K. W. Wong, D. L. Ma, C. H. Leung, Selective Inhibition of Lysine-Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple-Negative Breast Cancer Therapy.Angew. Chem. Int. Ed.57, 13091-13095 (2018).
Impact Factor:12.257
10.K. Vellaisamy, G. Li, C. N. Ko,H. J. Zhong, S. Fatima, H. Y. Kwan, C. Y. Wong, W. J. Kwong, W. Tan, C. H. Leung, D. L. Ma, Cell imaging of dopamine receptor using agonist labeling iridium(III) complex.Chem. Sci.9, 1119-1125 (2018).
Impact Factor:9.556
11.K. H. Leung, H. Z. He, B. He,H. J. Zhong, S. Lin, Y. T. Wang, D. L. Ma, C. H. Leung, Label-free luminescence switch-on detection of hepatitis C virus NS3 helicase activity using a G-quadruplex-selective probe.Chem. Sci.6, 2166-2171 (2015)
Impact Factor:9.556
12.C. H. Leung, S. Lin,H. J. Zhong, D. L. Ma, Metal complexes as potential modulators of inflammatory and autoimmune responses.Chem. Sci.6, 871-884 (2015)
Impact Factor:9.556
13.D. L. Ma, L. J. Liu, K. H. Leung, Y. T. Chen,H. J. Zhong, D. S. H. Chan, H. M. D. Wang, C. H. Leung, Antagonizing STAT3 dimerization with a rhodium(III) complex.Angew. Chem. Int. Ed.53, 9178-9182 (2014)
Impact Factor:12.257
14.K. J. Wu,H. J. Zhong (Co-first author), G. Yang, C. Wu, J. M. Huang, G. Li, D. L. Ma, C. H. Leung, Small Molecule Pin1 Inhibitor Blocking NF-κB Signaling in Prostate Cancer Cells.Chem. Asia J.13, 275-279 (2018)
Impact Factor:3.698
15.K. J. Wu,H. J. Zhong(Co-first author), G. Li, C. Liu, H. M. D. Wang, D. L. Ma, C. H. Leung, Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.Eur. J. Med.Chem.143, 1021-1027 (2018).
Impact Factor:4.833
16.L. Lu,H. J. Zhong(Co-first author), B. He, C. H. Leung, D. L. Ma, Development of a luminescent G-quadruplex-selective iridium(III) complex for the label-free detection of adenosine.Sci. Rep.6, (2016)10.1038/srep19368.
Impact Factor:4.122
17.H. J. Zhong(First author), S. Lin, I. L. Tam, L. Lu, D. S. H. Chan, D. L. Ma, C. H. Leung, In silico identification of natural product inhibitors of JAK2.Methods71, 21-25 (2015).
Impact Factor:3.782
18.H. J. Zhong(First author), K. H. Leung, S. Lin, D. S. H. Chan, Q. B. Han, S. L. F. Chan, D. L. Ma, C. H. Leung, Discovery of deoxyvasicinone derivatives as inhibitors of NEDD8-activating enzyme.Methods71, 71-76 (2015).
Impact Factor:3.782
19.L. Lu,H. J. Zhong(Co-first author), M. Wang, S. L. Ho, H. W. Li, C. H. Leung, D. L. Ma, Inhibition of Beta-Amyloid Fibrillation by Luminescent Iridium(III) Complex Probes.Sci.Rep.5, (2015)
Impact Factor:4.122
20.H. Yang,H. J. Zhong(Co-first author), K. H. Leung, D. S. H. Chan, V. P. Y. Ma, W. C. Fu, R. Nanjunda, W. D. Wilson, D. L. Ma, C. H. Leung, Structure-based design of flavone derivatives as c-myc oncogene down-regulators.Eur. J. Pharm. Sci.48, 130-141 (2013)
Impact Factor:3.532
发明专利：
Iridium(III)-based irreversible protein-protein interaction inhibitor of BRD4 as a potent anticancer agent. C.-H. Leung,H.-J. Zhong, D.-L. Ma, H.-M. Wang (US PatentNo.: 9,840,526 B1), 12, Dec, 2016
联系方式：
邮箱：hjzhong@jnu.edu.cn